Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.

Pharmacogenomics - 1 Aug 2011

van Schaik Ron H N, Kok Marleen, Sweep Fred C G J, van Vliet Martin, van Fessem Marianne, Meijer-van Gelder Marion E, Seynaeve Caroline, Lindemans Jan, Wesseling Jelle, Van 't Veer Laura J, Span Paul N, van Laarhoven Hanneke, Sleijfer Stefan, Foekens John A, Linn Sabine C, Berns Els M J J

Abstract excerpt

AIMS: Tamoxifen is metabolized by cytochrome P450s, with an important role for CYP2D6. Recently, we demonstrated in 80 patients that CYP2C19*2 is associated with increased survival in breast cancer patients using tamoxifen. Here, we aimed to confirm this in a large group of 499 patients. MATERIALS & METHODS: A total of 499 estrogen receptor-positive primary breast tumor specimens of advanced disease patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Data Interpretation, Statistical

Share to Lymphatic Metastasis

Share to Menopause

Share to Receptors, Progesterone

Share to Tamoxifen

Source

Identifiers

PMID: 21830868
DOI: 10.2217/pgs.11.54

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.PMID 21830868Read ↗

CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.Semantic proximity Read ↗

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.Semantic proximity Read ↗

CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.Semantic proximity Read ↗

Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay.Semantic proximity Read ↗

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse.Semantic proximity Read ↗

CYP2C19*17 is associated with decreased breast cancer risk.Semantic proximity Read ↗

Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.Semantic proximity Read ↗

Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen TherapySemantic proximity Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

Personalized tamoxifen: a step closer but miles to go.Semantic proximity Read ↗

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.Semantic proximity Read ↗

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.